Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma
by
Vennera, Maria del Carmen
, Picado, Cesar
, Sabadell, Carlos
in
Allergies
/ Asthma
/ Clinical trials
/ Failure
/ Monoclonal antibodies
/ Patients
/ Success
/ Thoracic surgery
2018
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma
by
Vennera, Maria del Carmen
, Picado, Cesar
, Sabadell, Carlos
in
Allergies
/ Asthma
/ Clinical trials
/ Failure
/ Monoclonal antibodies
/ Patients
/ Success
/ Thoracic surgery
2018
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma
Journal Article
Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma
2018
Request Book From Autostore
and Choose the Collection Method
Overview
Efficacy of omalizumab in severe asthma is well documented; however, the optimal duration of the treatment remains unclear. In an open prospective study, we sought to assess the persistence of response in subjects withdrawing from omalizumab treatment. We evaluated 49 patients who voluntarily accepted to discontinue omalizumab treatment after 6 years of therapy. Asthma relapse was defined as any severe asthma exacerbation associated with loss of asthma control. Twelve patients relapsed in the first year of follow-up, and 7 within 13 and 48 months. These results suggest that the effects of 6 years of omalizumab may persist after discontinuation of therapy in 60% of patients for at least 4 years.
Publisher
BMJ Publishing Group LTD
Subject
MBRLCatalogueRelatedBooks
Related Items
Related Items
We currently cannot retrieve any items related to this title. Kindly check back at a later time.
This website uses cookies to ensure you get the best experience on our website.